Victor S. Lin

476 total citations
15 papers, 283 citations indexed

About

Victor S. Lin is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Victor S. Lin has authored 15 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 4 papers in Oncology. Recurrent topics in Victor S. Lin's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (5 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Victor S. Lin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (5 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Victor S. Lin collaborates with scholars based in Australia, United States and Austria. Victor S. Lin's co-authors include Sasanka M. Handunnetti, Thomas E. Lew, John F. Seymour, Piers Blombery, Constantine S. Tam, Andrew W. Roberts, Mary Ann Anderson, David Westerman, David C.S. Huang and Bryone J. Kuss and has published in prestigious journals such as Blood, PLoS ONE and Journal of General Internal Medicine.

In The Last Decade

Victor S. Lin

15 papers receiving 279 citations

Peers

Countries citing papers authored by Victor S. Lin

Since Specialization

Citations

This map shows the geographic impact of Victor S. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor S. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor S. Lin more than expected).

Fields of papers citing papers by Victor S. Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor S. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor S. Lin. The network helps show where Victor S. Lin may publish in the future.

Co-authorship network of co-authors of Victor S. Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Victor S. Lin. A scholar is included among the top collaborators of Victor S. Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor S. Lin. Victor S. Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications 2024 ·British Journal of Haematology ·Mingyuan Gao, Angela Georgiou, Victor S. Lin, (unknown), Christine White, Mary Ann Anderson, Matthew P. McCormack, Andrew W. Roberts, David C.S. Huang, Rachel Thijssen	1
2	Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon 2024 ·Blood Advances ·Thomas E. Lew, (unknown), Victor S. Lin, (unknown), Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, (unknown), Piers Blombery, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Philip A. Thompson, Mary Ann Anderson	6
3	Definitions of massive transfusion in adults with critical bleeding: a systematic review 2023 ·Critical Care ·Victor S. Lin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Carolyn Dorée, Susan J Brunskill, Zoe McQuilten, Simon Stanworth, Erica M. Wood, Laura Green	18
4	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition 2021 ·Blood Advances ·Thomas E. Lew, Victor S. Lin, Edward R. Scheffer Cliff, Piers Blombery, Ella R. Thompson, Sasanka M. Handunnetti, David Westerman, Bryone J. Kuss, Constantine S. Tam, David C.S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson	45
5	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL 2021 ·Blood ·Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashis Kumar Panigrahi, Sasanka M. Handunnetti, Dennis Carney, David Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C.S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson	47
6	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months 2020 ·Blood Advances ·Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil Came, Piers Blombery, David Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour	31
7	Differences Between Current and Desired Physician Hypertension Management Roles Among Chinese American Seniors: a Qualitative Study 2020 ·Journal of General Internal Medicine ·(unknown), Victor S. Lin, (unknown), (unknown), Michael Ong, (unknown), Catherine A. Sarkisian	1
8	BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic 2020 ·Cancers ·Victor S. Lin, (unknown), David C.S. Huang, Rachel Thijssen	15
9	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax 2020 ·Blood ·Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti, Piers Blombery, Tamia Nguyen, David Westerman, Bryone J. Kuss, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Mary Ann Anderson	61
10	Feasibility of a Clinical Decision Support Tool to Manage Resistant Hypertension: Team-HTN, a Single-arm Pilot Study 2020 ·Military Medicine ·(unknown), Victor S. Lin, (unknown), (unknown)	1
11	Post-operative atrial fibrillation: should we anticoagulate? 2019 ·Annals of Translational Medicine ·(unknown), (unknown), (unknown), (unknown), Victor S. Lin, Rami N. Khouzam	14
12	PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL) 2019 ·Value in Health ·Olalekan O. Oluwole, Jeroen P. Jansen, Victor S. Lin, Keith Chan, Lynn Navale, (unknown), Frederick L. Locke	2
13	Venetoclax for the treatment of mantle cell lymphoma 2019 ·Victor S. Lin, Mary Ann Anderson, David C.S. Huang, Andrew W. Roberts, John F. Seymour, Constantine S. Tam	2
14	The Last Frontier: Catch Records of White Sharks (Carcharodon carcharias) in the Northwest Pacific Ocean 2014 ·PLoS ONE ·(unknown), Victor S. Lin, S. Tanaka, (unknown), Henry F. Mollet, Sabine P. Wintner, Sonja V. Fordham, Aaron T. Fisk, Nigel E. Hussey	24
15	Older adult consumers' attitudes and preferences on electronic patient-physician messaging. 2013 ·PubMed ·Richard Y. Lam, Victor S. Lin, (unknown), (unknown), Alison Moore, Brandon Koretz	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact